Immunocore laid out a 2026 agenda centered on expanding its melanoma franchise and advancing its TCR bispecific platform beyond...

Cellectis has set 2026 as a catalyst-heavy year, centering on a pivotal phase 2 trial for its off-the-shelf CAR-T,...

ImmuCell posted preliminary 2025 results and a strategic reset. Fourth-quarter sales reached $7.6 million, down 1.6% year over year,...

Day One Biopharmaceuticals reported preliminary 2025 net product revenue of $155.4 million for Ojemda, up 172% year over year,...

Nicox has repaid all secured debt owed to Kreos Capital and secured up to €4 million in new unsecured...

CorMedix Therapeutics has consolidated its leadership bench as it scales into a multi-brand anti-infectives and hospital products company. The...

Collegium Pharmaceutical set 2026 guidance at $805–$825 million in net product revenue with adjusted EBITDA of $455–$475 million, anchored...

Alvotech disclosed two insider transactions filed with the Luxembourg financial regulator: ATP Holdings ehf., identified as a manager or...

ATP Holdings ehf has acquired 6,922,897 shares in Alvotech across two market transactions on December 17 and December 19,...

ATP Holdings ehf. has filed two manager-and-related-party transactions with Luxembourg’s market regulator involving Alvotech: an acquisition of 4,812,257 shares...